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Title Midazolam use for dental conscious sedation: how safe are we? 
In brief  
 The use of midazolam for conscious sedation has an excellent safety profile in dentistry 
comparatively, with a low number of reported incidents 
 Use of high strength midazolam is still prevalent 
 Education and training of dentists regarding relevant safety reports and reporting systems is 
necessary to improve the safety culture of drug administration in conscious sedation.   
 
Abstract (200 words) 
 
Aim: To explore the safety awareness of midazolam use amongst dentist in the UK. Materials and 
methods: A cross-sectional study on 203 dentists was undertaken, 146 of whom currently practice 
conscious sedation using intravenous midazolam.  Use of high strength midazolam; awareness of the 
Rapid Response Report (RRR) and the National Reporting and Learning System (NRLS); and 
midazolam related incidents were explored. Results: Formal training in conscious sedation was 
variable with 35.6% holding a postgraduate sedation qualification. Flumazenil administration was 
common practice (63%) although used very selectively.  Use to reverse respiratory depression was 
minimal (4%).  Awareness of the RRR and the NRLS was generally low but higher among those 
working in general dental practice (p<0.05).  Comparative analysis showed that high dose midazolam 
was administered more frequently in gastroenterology than in dentistry (p<0.001) with higher 
incidences of overdose (12.4% Vs 4.8%) and death (8.3% Vs 0%) within a 3 year period. Conclusions: 
High strength midazolam administration remains prevalent in dentistry, despite recommendations 
by the DoH.  Use of flumazenil for reasons other than respiratory depression in dentistry should 
warrant little concern.  The low incidence of reported harm is positive but may be due to a lack of 
uptake of national reporting systems. 
 
 
Introduction 
The increasing level of dental anxiety in the UK population (1) has kept the demand for dental 
conscious sedation (CS) high.   General anaesthesia (GA) is an alternative but is not without 
significant morbidity, and the associated expense in today’s constrained health care funds make it 
less feasible (2). Side effects are uncommon with midazolam, although the risks associated with high 
doses are hypoventilation and hypoxemia (3)which can be reversed rapidly with flumazenil.  
Recommendations within medical guidance suggest that routine administration of flumazenil should 
be avoided, and use regularly audited as a marker of excessive midazolam use (4).   
 
Recent years have witnessed a shift towards safer practices in CS using midazolam- the result of key 
published documents (5).  In 2004, the National Confidential Enquiry into Patient Outcome and 
Death (NCEPOD) showed an increase in sedation related mortality/morbidity in the elderly resulting 
from high doses of benzodiazepines (6), further highlighted when 498 incidents of midazolam 
overdose were recorded on the National Reporting and Learning System (NRLS) between 2004-2008.  
The rapid response report (RRR) that ensued recommended high strength midazolam restriction to 
GA, palliative care and in risk assessed areas and that routine use of flumazenil should be avoided 
(7).   
 
Costing over £5m to develop, the NRLS has enabled nationwide incident reporting with the intention 
of learning in a blame free environment (8).  When an incident occurs in an NHS Trust, the onus is on 
staff to record information on a safety management system.  Sensitive information is anonymised, 
electronically sent to the NPSA (9) and stored in the NRLS’ data fields that include location, specialty, 
qualitative descriptions of the incident and level of harm: (1)No harm; (2)low harm; (3)moderate 
harm; (4)severe harm; (5)death (10). In April 2010, it became compulsory to report all serious harm 
or death following a serious patient safety incident to the NPSA who forward the data to the Care 
Quality Commission (11). 
 
Whilst there have been numerous studies exploring the safety of midazolam in medicine, little is 
known about the number of non-death related incidents nationally within dentistry.   To date, the 
safety awareness of midazolam use amongst dentists in the UK has not been established and the aim 
of this paper is to explore this and to follow on from previously published work that focused on 
safety in gastroenterology (12).  
 
Materials and Methods 
a. Data collection regarding the midazolam safety awareness in dentistry- questionnaire 
A cross sectional survey was distributed via an electronic portal to dentists practising intravenous 
sedation (IV) in the UK (Table 1).  Ethical approval was sought from City, University of London ethics 
committee. Questions explored background, use of different midazolam strengths (and high dose 
midazolam as specified by the Department of Health’s Never Events list) and flumazenil, adverse 
events, and awareness of the RRR and NRLS.  There was an option to express comments on 
questions for the online questionnaire should any participant feel they needed to add further 
information or clarify answers. The survey was also distributed during various national sedation 
meetings (SAAD conference and SAAD weekend courses) in order to capture the target group.  
Dentists currently practicing intravenous sedation (IVS) in the UK were included in the study.  All 
participants were able to withdraw from the study at any time.   As sedation is not recognised as an 
independent specialty, eliciting the numbers of sedation dentists in the UK from the General Dental 
Council register was impossible.   Nevertheless, the minimum sample size was based on a similar 
previous report that studied sedation incidents in gastroenterology (12).   
b. Comparative analysis with gastroenterology 
Questions used in a previously published study (12) that explored midazolam related incidents in 
gastroenterology were incorporated into our survey to allow raw data comparisons between 
gastroenterology and dentistry.  The involvement of one of the authors in this previous study 
enabled access to raw data, facilitating comparative analysis. 
 
Data from questionnaires was analysed with SPSS v21 using Pearson's Chi-square (χ2) to identify 
differences in practice, awareness and occurrence of incidents between groups in methods a and b 
(comparing IVS dentists with non IVS dentists; and dentists with gastroenterologists).  Differences 
were considered statistically significant when P < 0.05.  All ‘don’t know’ responses were included in 
the analysis of data.  
 
 
c. Analysis of incident data from the NPSA 
Incidents in dentistry from the NRLS database were requested from NHS England.  The NRLS 
database was examined for midazolam related dental incidents from 1st January 2005 to 4th October 
2015 using the following keyword searches: MIDAZALOM, MIDAZELAM, MIDAZILEM, MIDAZOLAM, 
MIDIZOLAM, MIDOZALAM, MIDOZOLAM, HYPNOVAL, HYPNOVEL, FLUMAZENIL, FLUMAZIMIL, 
ANEXATE, ANNEXATE combined with DENTISTRY, DENTAL, DENTIST.   Details of incidents such as 
type of incident, level of harm and details of incident were analysed and summarised in the results 
below.  Removal of duplicate incidents and inspection of free-text legends confirmed the relevance 
of the incident for analysis.   
 
 
 
  
Results 
Responses received totalled 212, with 9 incomplete submissions which were omitted from analysis. 
Of the remaining 203 responses, 146 dentists stated that they currently carry out IVS.   As some of 
the data was collected during the SAAD weekend course, there were some participants who were 
new to conscious sedation practice and had no experience of IVS or were not regularly practicing 
IVS.  Participants who stated that they ‘never’ carry out IVS were included in the data analysis for 
comparative purposes, dividing the data into two groups: IVS dentists (71.9%, n=146 ) and non IVS 
dentists (28.1%, n=57). 
 
The total rate of response is unknown as the link to the survey was originally sent to a defined 
number of people but was then subsequently disseminated via email to an unknown number of 
recipients.   
 
Survey responses amongst dentists 
Background of clinicians 
The median number of years since qualification for both groups was 9.5 years (s.d.=9.44, IQR 4.0-
16.3yrs) amongst IVS dentists, and 5.0yrs (s.d.= 8.4 years, IQR 3.0-15.0 years) amongst non IVS 
dentists.  General dental services, GDS, (46.6%, n=68) were the most common place of work for 
participants in the IVS group, followed by hospital dental services, HDS, (30.8%, n=45), with smaller 
numbers practicing in community dental services, CDS, (15.8%, n=23) and specialist dental practices, 
SDS (2.7%, n=4).   The majority of non IV sedation dentists were in hospital dental services (57.9%, 
n=33) and in GDP (17.5%, n=10) 
 
Training and experience 
Training in conscious sedation amongst IVS dentists was mainly via a weekend course (IVS dentists 
39.0%, n=57; non IVS dentists 93%, n=33) hosted by SAAD, the biggest sedation society in the UK.  
Those with a postgraduate sedation qualification comprised 35.6% of IVS dentists (n=52).  The 
remainder of participants had in house training or had attended a CPD course in sedation.  A 
postgraduate qualification in sedation was more common amongst dentists in GDS (n=30, 20.5%) 
than HDS (n=11 7.5%), but this difference was not statistically significant (χ2(4)=4.81, p=0.307, 
ϕ=0.182).  Those with a postgraduate qualification were significantly more likely (U=1826.5, 
p=0.011) to have been qualified for longer (median=11years, IQR=3-15.25 years) than those without 
(median=7years, IQR=6.25-18.75) (Figure 1). 
 
The experience of IVS dentists was variable, with many carrying out sedation less than 20 times a 
year (32.9%, n=48) or more than 80 times a year (31.5%, n=46).  General dental practitioners 
provided the majority of IV sedation compared to hospital practitioner who were more likely to carry 
out less than 20 sedation treatments a year (χ2(16)=27.79, p=0.034, ϕ=0.436).    
 
Drug administration 
Some sedation dentists declared that low strength midazolam was not available for use 
intravenously in their clinics (17.8%, n=26).  Most reported no midazolam related incidents (93.8%, 
n=137) that required major intervention, and in those who did- none reported any level of harm or 
death.  There was no significant difference between place of work and use of high strength 
midazolam (χ2(12)= 15.184, p=0.232, ϕ=0.322) or availability of low strength midazolam 
(χ2(8)=12.840, p=0.117, ϕ=0.297).  Over a third (32.9%) of IVS dentists used high strength midazolam 
intravenously (21.9%, n=32), and orally as a pre-medication prior to IV administration (10.96%, 
n=11).   Intravenous administration of high strength midazolam was significantly (χ2(9)=21.162, 
p=0.012, ϕ=0.381) more common in those qualified in the last 5 years (43.8%) than practitioners 
qualified for over 15 years (28.1%) but the majority of those using it orally as a pre-medication had 
been qualified over 10 years (90.9%).   There was no statistically significant association between use 
of high strength midazolam and midazolam related incidents (χ2(6)=1.925, p=0.926) 
  
Flumazenil use 
 
Flumazenil administration was common practice (53% of responses) (Figure 2) with its main uses 
including prolonged chairside recovery (22%, n=45), and for patients with learning disabilities (15%, 
n=32) and mobility problems (12%, n=26).  Reversal of respiratory depression was the reason for 
delivery in 4% of cases (n=9). 
 
Awareness of the RRR guidance 
Only 47.3% (n=66) of IVS dentists were aware of the RRR compared to 22.8% (n=13) of non IVS 
dentists (Fisher’s exact p=0.001).  They were also significantly more likely to know who their RRR 
lead was (31.5%, n=46 Vs 12.3%, n=7; Fisher’s exact p=0.011) and were more aware of the NRLS 
reporting system (44.5%, n=65 Vs 22.8%, n=13; Fishers Exact p=0.006).  Awareness of the RRR 
(χ2(4)=14.054, p=0.007, ϕ=0.310) and NRLS (χ2(4) =14.117, p=0.007, ϕ=0.311) was higher in GDS and 
those with a postgraduate qualification (RRR: Fisher’s exact=24.764 p<0.001, ϕ=-0.413; NRLS Fisher’s 
exact=4.109 p=0.043, ϕ=-0.168).  
 
Comparative data with gastroenterology 
High dose midazolam was administered more frequently in gastroenterology than in dentistry 
(χ2(4)=57.4, p<0.001).   No significant differences were observed between the two professions in 
reference to midazolam strengths and incidents, despite reported incidents being higher in 
gastroenterology, with one incident of long term harm or death (Table 2).  Gastroenterologists were 
significantly more likely to have administered high strength midazolam in the last 3 years 
 
 
  
 Data from the NRLS 
After excluding data that was repeated or unrelated to dentistry, a total of 57 incidents were 
obtained from the NRLS over a 10year period.  Incidents occurred mainly in GDS (49.12%, n=28) and 
HDS (43.86%, n=25), with a minority in CDS (7.02%, n=4).  No harm was reported in 87.72% (n=50) of 
patients, low harm in 8.77% (n=5) and moderate harm in 3.51% (n=2).  Serious harm or death was 
not reported in any cases.  Qualitative data entries were analysed in detail to elicit whether the level 
of harm assigned corresponded with the details of the incident.  These were all individually validated 
for consistency by the authors, all experts in the field of sedation, incident reporting, patient safety 
or medical error reviews.   The two cases of moderate harm were: a fit and faint that occurred after 
administration of 2mg midazolam; and shaking with wheezing after administration of local 
anaesthesia sometime after 7mg midazolam was administered. 
The main findings of the reported incidents are summarised in Table 3.  Incidences of respiratory 
depression was very low (2%, n=1).  The most frequently cited incident was shattering of the 
midazolam ampoule (33%, n=19).  Flumazenil was wrongly administered instead of midazolam in 9% 
of incidents but in all these cases, treatment was carried out as planned without subsequent 
administration of midazolam and the patient was informed.  In one case, the confusion was due to 
the similarity in the appearance of the midazolam and flumazenil ampoules.  Resedation after 
40minutes of flumazenil administration was recorded in one incident.  The patient was monitored 
and fully recovered thereafter.  
 
 
Discussion 
Historically, anaesthetists have scrutinised the use of conscious sedation drugs in dentistry, 
advocating the sole use by medical professionals (13,14,15).  This may partly be due to the limited 
evidence regarding the safety record of midazolam administration in dentistry, a prime objective of 
this study.   
 
The NPSA guidance was significant, with the hope that it would reduce incidents in CS.  It is 
surprising that the awareness of the report was low, though this finding relates to the name of the 
guidance and not knowledge regarding best practice procedures that resulted from the RRR’s 
recommendations i.e. the replacement of high strength with low strength midazolam.  However, our 
results showed the concentrated formulations are still widely used irrespective of sector.  Although 
some dentists were using high strength midazolam orally as a premedication to allow cannulation in 
special care patients, a high proportion (32.9%) used it intravenously. Absence of low dose 
midazolam as declared by 17.8% of our sample may be due to cost implications, with the 
concentrated formulations being cheaper per unit ml (10mg/2ml ampoules=63p; 10mg/5ml= 65p; 
5mg/5ml=60p).  Comparative data with gastroenterology showed that dentists were using 
significantly less high strength midazolam, which may be why there were less reported incidents 
(4.8% compared to 12.4% in gastroenterology) in dentistry. This could also be due to the low 
reporting culture within dentistry, especially in primary care which contributes just 5% to all incident 
reports to the (16).  Nevertheless, the low number of incidents suggest that midazolam as a CS drug 
in dentistry is safe, concurring with a recent systematic review focusing on the safety of oral 
midazolam in paediatric patients (17).  We suggest that alternatives for pre-medications such as 
2.5mg/ml oral syrup should be explored.  It should also be noted that the use of intranasal 
midazolam (40mg/ml) was not explored in this survey, and is therefore a limitation of this study. 
We intended to explore purchasing data of midazolam and flumazenil to ascertain reductions in 
purchasing of high strength midazolam since the RRR guideline, but the NHS Purchasing and Supply 
Agency that had provided global purchasing data within the NHS in a previous study (12) was 
dissolved in 2010.   Data was thus requested from various pharmaceutical companies for the period 
of 2008-2015, however we received no response. 
 
Serious harm or death resulting from high strength midazolam (5mg/ml; 2mg/5ml) overdose during 
conscious sedation is a UK Department of Health ‘Never Event’ (18) which must be reported, most 
commonly through a tool such as the NRLS (19). However, our data highlighted flaws with this 
system.  For example, the qualitative data described medical emergencies that ensued following 
administration of the drug, which may in fact be two isolated incidents.  Thus, the taxonomy may 
confuse or hide incidents (20).  Furthermore, NLRS reports refer to incidents for patients receiving 
NHS funded care.  Exclusion of the private sector can account for the low number of reported 
incidents compared to medicine.   A tailored systematic monitoring safety system within dentistry 
would provide a more reliable evidence base, and may incentivise its use. Improvements in reporting 
could increase the number of incidents in the long term as reflected in the data received by NHS 
England which exhibited a 6% increase in incidents in one year (21).  Furthermore, the statutory duty 
of candour which emphasises the need to be transparent to patients when an incident occurs and to 
report it may increase incident reporting (22).   
 
Although the RRR suggested that administration of flumazenil is indicative of a benzodiazepine 
overdose, its use in dentistry is for reasons other than to reverse respiratory depression as indicated 
in all our data, supporting earlier findings (23).  Flumazenil can prevent sedation-related accidents 
after dental procedures in those with mobility problems and severe learning disabilities, who have 
been shown to be at an increased risk of falls and injury (24).  Hence concerns regarding use of 
flumazenil as a surrogate marker of midazolam overdose requiring reversal should not be a 
deterrent for its administration in dentistry provided it is justified with appropriate measures to 
avoid errors.  The NRLS data showed that there were 9% of incidents involving wrong administration 
of flumazenil instead of midazolam, which is similar to reported national medicines administration 
errors of 3-8% (25).    Similar drug packaging may contribute to human factor error, as explained in 
one data entry from the NRLS.  For example, flumazenil and midazolam are available from 
manufacturers in packaging of a similar colour (Figure 3) which has previously been identified as  
increasing the risk of medicines administration errors (26), (27) (7). 
 
 
 
 
 
 
 
 
A strong primary care base of dentists qualified and experienced in carrying out CS is essential in 
view of recent NHS sustainability reports (28) and our results are encouraging as they showed more 
dentists with a PG qualification in general practice carrying out sedation.   Over a third (35.6%) of our 
sample had a sedation PG qualification, which is similar to the documented uptake of sedation 
training by medical non-anaesthetists (29).  The impact of new UK conscious sedation guidelines is 
likely to enhance the uptake of PG accredited training programmes within dentistry, thereby 
improving knowledge and awareness of safety practices recommended in key documents such as 
the RRR. 
Although the results are positive, we appreciate that this study is not without limitations/challenges.  
There was no way of identifying exactly the number of dentists currently practicing sedation and we 
cannot therefore elicit to what extent our survey sample represents the views of all IVS dentists.  
However, we believe that we maximised the number of responses by utilising our dental 
professional network which has been shown to be an effective method of information gathering (30)  
 
We also recognise that there are limitations with self-reporting of adverse events in dentistry, which 
is in part due to: (1) failure in incident recognition, (2) apprehension of medico-legal liability (3) 
behavioural inclinations not to publicly acknowledge adverse (4) lack of knowledge about the 
processes of reporting (31,32,33).  Despite this, our collection of incident and awareness data 
provides a useful and informative snapshot that illustrates the safety of midazolam use in dentistry 
 
Conclusion 
The absence of reported harm and the low number of incidents suggest that midazolam as a 
conscious sedation drug in dentistry is safe.  Although there is little advice available on use of 
flumazenil for reasons other than respiratory depression, the use of flumazenil in dentistry should 
warrant minimal concern, as it is used selectively.  The low awareness of the NRLS and RRR 
emphasises the need to act and learn from patient safety incidents in a blame free environment 
through improved incident reporting.  In view of recent published guidance, more training 
programmes need to be made available to coordinate the delivery of training in safe sedation 
practice in dentistry and increase awareness of key policies and reports 
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Figure Legends 
 
Figure1 Box plot showing that dentists with a postgraduate qualification in sedation were more likely 
to have been qualified longer (11 years Vs 7 years) (U=1826.5, p=0.011) 
Figure 2: Bar chart showing the clinical situations in which flumazenil is used.  Most clinicians 
reported never using flumazenil, with the smallest percentage reporting its use to reverse respiratory 
depression 
Figure 3:  Flumazenil and midazolam drug ampoules (5ml) manufactured by Hameln 
Pharmaceuticals, Gloucester, UK.  The similarity between the packaging could account for the miss 
selection drug errors  
 
  
Tables 
About you 
Year of graduation: 
Place of work: (Tick all that apply) 
o General Dental Practice 
o Community Dental Service 
o Hospital Dental Service 
o Other (please specify) 
Have you attended any post-graduate training courses in conscious sedation? Please tick all that apply: 
o SAAD course 
o Certificate in conscious sedation 
o Diploma in conscious sedation 
o MSc involving conscious sedation 
o Other (please specify) 
o Comments 
Your Experience 
How often do you treat patients under intravenous sedation 
o Never 
o Less than 20x/year 
o 21-40x/year 
o 41-60x/year 
o 61-80x/year 
o 80+ times/year 
 
Have you administered intravenous high-strength midazolam in the last 3 years for conscious sedation (10mg in 2ml, 10mg/5ml)? 
o Yes, intravenously 
o Yes, as an oral pre-medication 
o No 
o Don't know 
Is intravenous low-strength midazolam (5mg /5ml) routinely available in your dental clinic? 
o Yes 
o No 
o Don't know 
o Details 
Have you been involved in a midazolam overdose incident in the past 3 years whereby the patient failed to respond to simple measures of 
opening the airway, oxygen therapy and tactile stimulation? 
o Yes 
o No 
o Don't know 
If you answered yes to the previous question, did this incident result in death or long-term harm to the patient? 
o Yes 
o No 
o Comments 
In what circumstances have you had to use flumazenil in the past? (* tick all that apply) 
o Never used flumazenil 
o For prolonged chairside recovery 
o For those travelling long distances 
o For patients with mobility problems 
o For patients with learning disabilities (to assist carers) 
o To reverse respiratory depression 
o other- please specify below in comments box 
Prior to this survey, were you aware the National Patient Safety Agency had issued an Rapid Response Report regarding midazolam? 
o Yes 
o No 
o Comments 
Do you know who the lead for implementing this Rapid Response Report is in your organisation/practice? 
o Yes 
o No 
o Comments 
Were you aware of the National Patient Safety Agency's national reporting and learning system for recording patient incidents? 
o Yes 
o No 
o Comments 
Table 1 Questionnaire distributed to dentists across the UK  
 Profession Question 
 Have you administered high strength midazolam in the last 3 years?* 
 Yes % (n) No Don’t know 
Dentistry 32.9 (48) 67.1 (98)  0.0 (0) 
Gastroenterology 68.0 (66)* 30.9 (30) 1 (1) 
 Is low strength midazolam available in your clinic? 
 Yes No Don’t know 
Dentistry 79.5 (116) 17.8 (26) 2.7 (4) 
Gastroenterology 81.4 (79) 16.5 (16) 2.1 (2) 
 Have you been involved in a midazolam related overdose in past 3 years? 
 Yes No Don’t know 
Dentistry 4.8 (7) 93.9 (137) 1.4 (2) 
Gastroenterology 12.4 (12) 86.6 (84) 1 (1) 
 If you answered yes, did this result in long term harm or death? 
 Yes No Don’t know 
Dentistry 0 100.0 0.0 
Gastroenterology 8.3 (1) 91.7 (11) 0.0 
*Significant difference observed between gastroenterology and dentistry  
Table 2 Comparative responses between gastroenterologists and dentists regarding midazolam and 
incidents 
  
Medication Error Category  % (n) 
Re-sedation after flumazenil 2 (1) 
High strength midazolam wrongly administered 4 (2) 
Flumazenil mistakenly administered 9 (5) 
Shattering of ampoule 33 (19) 
Medical emergency 18 (10) 
Respiratory depression 2 (1) 
Expired drug not administered 9 (5) 
Expired drug administered 2 (1) 
Missing drug unaccounted for 12 (7) 
Other 11 (6) 
Total 100 (57) 
Table 3:  Incidents relating to midazolam sedation in dentistry reported to the NRLS between 2007-
2015 
 
 
 
 
